Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | July 01, 2017 | July 06, 2017 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | February 18, 2020 | February 19, 2020 |
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 01, 2017 · Filed July 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 59,064 |
Reported balance
After 2017-07-01 transaction · row 1
1 source rowRow 1 · 2017-07-01 · Tax withholding · Disposed 613 · Balance 59,064 |
| Common shares without par valueSEC Table I · non-derivative | IndirectHeather L. Mason 2016 GRAT | 70,000 |
Reported balance
Holding disclosure · report date 2017-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 70,000 |
Assertio Therapeutics, Inc
Report date February 18, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,394 |
Reported balance
After 2020-02-18 transaction · row 1
1 source rowRow 1 · 2020-02-18 · Exercise / conversion · Acquired 14,394 · Balance 14,394 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-18 | Direct | 28,788 |
Reported balance
After 2020-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-18 · Exercise / conversion · Disposed 14,394 · Balance 28,788 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: One-third of these restricted stock units are scheduled to vest on each of February 18, 2020, 2021 and 2022, assuming continued service through the applicable vesting date.
F3: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Assertio Holdings, Inc.
Report date June 16, 2026 · Filed June 16, 2026
Section 16 reporting ended · disclosed 2026-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Other · Disposed 20,944 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-06-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-16 · Other · Disposed 6,666 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2] F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-16 · Disposition to issuer · Disposed 36,666 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 | Direct | 0 |
Reported balance
After 2026-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-16 · Disposition to issuer · Disposed 5,415 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]
F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $58.42 | $110,998.00 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 12 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,891 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $58.42 | $5,841.90 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 11 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,791 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $58.42 | $5,841.75 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 10 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,891 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $58.42 | $245,343.00 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 9 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,991 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $58.41 | $17,523.00 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 8 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,191 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $58.41 | $23,362.00 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 7 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,491 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $58.40 | $99,280.00 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 6 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,891 Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,045 | $56.35 | $284,285.75 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 5 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,516 | $54.62 | $738,243.92 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,822 | $48.79 | $625,585.38 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 962 | $49.38 | $47,503.56 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2012 Filed Mar 15, 2012 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,434 | $55.66 | $413,776.44 |
DisclosureSEC source: 0001179110-12-005118 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 761 | $56.74 | $43,179.90 |
DisclosureSEC source: 0001179110-12-004081 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,812 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $56.74 | $45,394.40 |
DisclosureSEC source: 0001179110-12-004081 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,573 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,800 | $57.04 | $558,992.00 |
DisclosureSEC source: 0001179110-12-004081 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,373 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 41,200 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003245 · edgar.xml · derivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common shares · 41,200 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,734 on 02/17/2013, 13,733 on 02/17/2014, and 13,733 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003245 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,173 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 53,201 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · derivative · entry 25 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 53,201 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 330 | $56.22 | $18,552.60 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 24 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,273 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $56.22 | $123,673.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 23 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,603 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $56.21 | $140,525.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 22 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,803 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $56.21 | $67,446.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 21 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,303 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,100 | $56.20 | $342,820.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 20 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,503 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $56.20 | $16,859.25 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 19 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,603 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,000 | $56.20 | $337,170.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 18 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,903 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $56.19 | $78,666.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 17 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,903 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.19 | $5,618.75 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 16 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,303 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.19 | $11,237.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 15 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,403 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $56.18 | $28,090.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 14 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,603 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $56.18 | $44,940.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 13 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,103 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,509 | $56.17 | $309,440.53 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 12 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,903 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 13,800 | $56.17 | $775,077.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 11 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,412 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,062 | $56.16 | $59,641.92 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 10 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,212 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $56.16 | $73,001.50 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 9 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,274 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $56.15 | $33,690.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 8 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,574 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $56.15 | $50,530.50 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 7 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,174 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $56.14 | $106,666.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 6 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,074 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $56.14 | $134,724.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 5 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,974 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $56.13 | $61,743.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,374 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,800 | $56.13 | $101,025.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 3 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,474 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $56.12 | $67,338.00 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 2 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,274 Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 53,201 | $53.63 | $2,852,903.63 |
DisclosureSEC source: 0001179110-11-017304 · edgar.xml · nonDerivative · entry 1 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.41 | $16,323.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 11 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,273 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,605 | $54.40 | $87,312.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 10 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,573 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,076 | $54.39 | $276,083.64 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 9 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,178 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,928 | $54.38 | $159,224.64 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 8 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,254 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,196 | $54.37 | $65,026.52 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 7 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,182 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.36 | $16,308.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 6 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,378 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $54.35 | $16,305.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 5 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,678 Read SEC document |
| November 11, 2011 Filed Nov 15, 2011 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $54.34 | $5,434.00 |
DisclosureSEC source: 0001179110-11-015196 · edgar.xml · nonDerivative · entry 4 Mason Heather L · CIK 0001432601 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,978 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.